Report | November 2017
PAYING FOR VALUE: How value-based Product Listing Agreements (PLAs) will drive better health outcomes and greater productivity in the workplace

The growing cost and volatility of drug plans, driven by the growth in specialty and high-spend drugs, are threatening the sustainability of benefits plans. Employers, generally not satisfied with current drug management solutions, are looking for a more holistic, evidence-based approach to pharmacy benefits management. This new reality is challenging players across the private payer value chain to rethink their positioning and offering.